BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12707720)

  • 1. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.
    Schaich M; Schäkel K; Illmer T; Ehninger G; Bornhäuser M
    Ann Hematol; 2003 May; 82(5):303-4. PubMed ID: 12707720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
    Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
    Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
    [No Abstract]   [Full Text] [Related]  

  • 7. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
    Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
    Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study].
    Liu L; Liu Q; Hao MW; Chen RA; Zhang JL; Wang LH; He H; Jiang SS; Liang YM
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1102-5. PubMed ID: 16029566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
    Weisser M; Schmid C; Schoch C; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1017-8. PubMed ID: 16184176
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
    Zaucha JM; Prejzner W; Giebel S; Gooley TA; Szatkowski D; Kałwak K; Wojnar J; Kruzel T; Balon J; Hołowiecki J; Hellmann A
    Bone Marrow Transplant; 2005 Sep; 36(5):417-24. PubMed ID: 16007105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
    Maziarz RT; Mauro MJ
    Bone Marrow Transplant; 2003 Sep; 32(5):459-69. PubMed ID: 12942091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of chronic myelogenous leukemia in 2004].
    Hochhaus A; Berger U; Hehlmann R
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.